However, the genomic status and expression of upstream LT/LTR, NIK (MAP3K14) signal and RELB transactivating components of the alternative NF-B pathway in HNSCC tumors has not been established

However, the genomic status and expression of upstream LT/LTR, NIK (MAP3K14) signal and RELB transactivating components of the alternative NF-B pathway in HNSCC tumors has not been established. a NIK inhibitor (1,3[2H,4H]-Iso-Quinoline Dione) reduced the protein expression of NIK and